NCT07659938Not yet recruiting
Frontal Gamma Coherence Neurofeedback for Patients With Schizophrenia
Preliminary Placebo-Controlled Double-Blind Randomized Clinical Trial of Mobile Platform to Improve Memory From Home or Office for Patients With Schizophrenia
Source: ClinicalTrials.gov · Last updated 24 Sept 2026
Brief summary (registry, in English)
This preliminary, randomized, double-blind, placebo-controlled clinical trial will evaluate frontal gamma coherence neurofeedback in adults with schizophrenia. Thirty participants will be randomly assigned to receive either active neurofeedback or placebo neurofeedback using a study-provided mobile platform. Participants will complete baseline assessments in person at the University of California San Diego, receive training on home use of the neurofeedback platform, and complete twice-weekly 30-minute sessions at home for 12 weeks. Participants will return for midpoint and end-of-treatment assessments to evaluate feasibility, tolerability, cognitive outcomes, and neurophysiological target engagement.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 15 Jun 2026
- Start date
- Apr 2027
- Primary completion date
- Jun 2028
- Lead sponsor
- BioSignal Solutions LLC
- Diseases
- Schizophrenia
- NCT number
- NCT07659938
What you commit to
- Study type: Interventional
- Planned participants: 30
- From Apr 2027 to the primary completion date, Jun 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Electroconvulsive therapy within six months of the baseline assessment;
- Medical conditions that can impact cognition, including self-reported history of seizure disorder; multiple sclerosis; stroke or major vascular disease; HIV/AIDS; brain cancer; prior head injury involving loss of consciousness;
Other illness
- Substance use disorder other than nicotine or caffeine in the past year;
Lab values
- Uncooperativeness with the laboratory assessment protocol leading to missing data;
Other
- Current (but not past) major depression;
- Inability to read or speak English (with corrected vision or hearing if needed);
- Unable to adequately see or manually manipulate a smartphone, tablet or other mobile device;
- Color blindness that interferes with assessment;
- Testing in the past 6 months on the cognitive measures
Who the study is looking for
- Voluntary informed consent to participate and capacity to consent as measured by the University of California, San Diego Brief Assessment of Capacity to Consent (UBACC1) instrument;
- Age 18 to 55;
- Meet DSM-5 criteria for a current diagnosis of schizophrenia or schizoaffective disorder based on a SCID-5 interview and available medical record review;
- Clinically stable as operationalized by (a) not having been admitted to a psychiatric hospital within the three months prior to assessment, (b) having had no change in antipsychotic medication dosage within four weeks prior to the baseline assessment, and (c) ascertained to be clinically and medically stable by one of the study investigators
Age in the registry: 18 years to 55 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of California San Diego Coordinator of this site? Confirm its status | La Jolla | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.